Anayiotos Andreas S, Pedroso Pedro, Advincula Maria A, Venugopalan Ramakrishna, Eleftheriou Evangelos C, Holman William L
Department of Biomedical Engineering, University of Alabama at Birmingham, Birmingham, Alabama 35294-4440, USA.
Technol Health Care. 2003;11(1):21-39.
Flow Streamlining Devices is a new tool in Coronary Artery Bypass Grafting (CABG). They aim in: a) Performing a sutureless anastomosis to reduce thrombosis at the veno-arterial junction, and b) Providing a hemodynamically efficient scaffolding to reduce secondary flow disturbances. Thrombosis and flow disturbances are factors that have been reported as contributing factors to the development of intimal hyperplasia (IH) and failure of the graft. By reducing thrombosis and flow disturbances, it is expected that IH will be inhibited and the lifetime of the graft extended. To evaluate the hemodynamic benefits of such an implant, two models were designed and fabricated. One simulated the geometry of the conventional anastomosis without an implant, and the other simulated an anastomosis with a flow streamlining implant. Identical flow conditions relevant to a coronary anastomosis were imposed on both models and flow visualization was performed with dye injection and a digital camera. Results showed reduction of disturbances in the presence of the implant. This reduction seems to be favorable to hemodynamic streamlining which may create conditions that may inhibit the initialization of IH. However, the compliance and geometric mismatch between the anastomosis and the implant created a disturbance at the rigid compliant wall interface, which should be eliminated prior to clinical applications.
血流优化装置是冠状动脉旁路移植术(CABG)中的一种新工具。它们旨在:a)进行无缝合吻合以减少动静脉交界处的血栓形成,以及b)提供一个血流动力学高效的支架以减少二次血流紊乱。血栓形成和血流紊乱是已被报道为内膜增生(IH)发展和移植物失败的促成因素。通过减少血栓形成和血流紊乱,预计IH将受到抑制,移植物的寿命将延长。为了评估这种植入物的血流动力学益处,设计并制造了两种模型。一种模拟了没有植入物的传统吻合术的几何形状,另一种模拟了带有血流优化植入物的吻合术。将与冠状动脉吻合相关的相同血流条件施加于两种模型,并通过染料注射和数码相机进行血流可视化。结果显示在有植入物的情况下干扰减少。这种减少似乎有利于血流动力学优化,这可能会创造出可能抑制IH起始的条件。然而,吻合术与植入物之间的顺应性和几何不匹配在刚性顺应性壁界面处产生了干扰,在临床应用之前应予以消除。